North America Autoimmune Disease Diagnostics Market Size & Forecast 2025–2033

North America Autoimmune Disease Diagnostics Market Overview

As per Renub Research study North America Autoimmune Disease Diagnostics Market was valued at USD 1.96 billion in 2024 and is projected to reach USD 3.5 billion by 2033, growing at a compound annual growth rate (CAGR) of 6.66% during the forecast period 2025–2033. This growth is attributed to an increase in autoimmune disease cases, higher public awareness, advances in diagnostic technologies, and increased healthcare spending across the region.

Autoimmune disease diagnostics involve laboratory assays and imaging techniques used to detect and monitor illnesses where the body’s immune system attacks its own tissues. Common autoimmune diseases include rheumatoid arthritis, lupus, multiple sclerosis, and type 1 diabetes. Early detection, accurate classification, and effective monitoring of these diseases are crucial for improving patient outcomes and quality of life.

The North American market is expanding due to the higher prevalence of autoimmune diseases among women and aging populations, advanced diagnostic platforms, and increased adoption of personalized medicine. Hospitals, diagnostic centers, and specialty clinics are investing in sophisticated technologies to meet rising demand, making this market a vital component of the regional healthcare landscape.

👉 Want to explore detailed market trends, segment insights, and forecasts? 🔗 Request Free Sample Report

Market Growth Drivers

1. Rising Prevalence of Autoimmune Diseases

North America has seen a steady rise in autoimmune conditions such as rheumatoid arthritis, lupus, and type 1 diabetes, driven by factors like sedentary lifestyles, genetics, and environmental influences. This growing prevalence emphasizes early detection and timely intervention, fueling demand for advanced diagnostic tests.

For example, the incidence of celiac disease in the U.S. has increased fivefold over the last 30 years, highlighting the urgent need for effective screening and monitoring. Medical professionals are increasingly prioritizing early detection, which enhances the adoption of sophisticated diagnostic methods and supports market expansion.

2. Advancements in Diagnostic Technologies

Innovations in molecular diagnostics, biomarker discovery, and next-generation sequencing have transformed the autoimmune diagnostics landscape. These technologies allow faster, more accurate, and precise results, enabling clinicians to customize treatment plans.

Leading firms and research institutions in North America continue to invest in R&D to enhance diagnostic capabilities. For instance, in February 2025, YESINTEK (ustekinumab-kfce) was launched in the U.S., targeting Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Similarly, Biocon Biologics introduced a biosimilar medicine for treating specific autoimmune conditions, reflecting the convergence of diagnostics and therapeutic innovation.

3. Well-Established Healthcare Infrastructure and Reimbursement Policies

North America’s robust healthcare infrastructure and comprehensive reimbursement frameworks encourage patients to access diagnostic services without significant financial burden. Hospitals, specialty clinics, and diagnostic centers provide sophisticated testing and monitoring platforms, enabling early detection and chronic disease management.

For example, in April 2025, the U.S. approved a 5.06% increase in reimbursement rates for Medicare Advantage plans in 2026, enhancing patient access to healthcare services. These policies, combined with government funding for chronic disease management, support market growth.

Market Challenges

1. High Cost of Advanced Diagnostics

While technological advancements improve accuracy, sophisticated diagnostic tests are expensive, involving costly equipment, infrastructure, and specialized staff. This financial barrier limits access for uninsured or underinsured individuals, particularly in rural regions, and restricts market penetration.

2. Diagnostic Complexity and Disease Overlap

Autoimmune disorders often present with non-specific symptoms, making differential diagnosis challenging. Overlapping symptoms with other conditions can lead to misdiagnosis or delayed diagnosis, complicating treatment planning. Additionally, many biomarkers are not disease-specific, requiring further R&D and clinician training to improve diagnostic accuracy.

Segment Analysis

Product Segments

Therapeutic & Monitoring Equipment: Devices and platforms for ongoing disease monitoring.

Diagnostics Equipment: Laboratory and imaging tools for disease identification.

Drugs: Biologics, immunosuppressants, and biosimilars for treatment.

👉 For deeper analysis, detailed segment data, and company insights: 🔗 Request Customization Report

Type Segments

Systemic Autoimmune Diseases: Conditions like systemic lupus erythematosus and multiple sclerosis, requiring complex diagnostics.

Localized Autoimmune Diseases: Conditions such as psoriasis and Hashimoto’s thyroiditis, diagnosed through tissue biopsies, hormone tests, and clinical evaluations.

Indication Segments

Rheumatic Disease: Rheumatoid arthritis, scleroderma, and related conditions.

Diabetes: Type 1 diabetes, requiring autoantibody testing and glucose monitoring.

Multiple Sclerosis: Neurological autoimmune disorder necessitating advanced imaging and lab tests.

Inflammatory Bowel Disease: Crohn’s disease, ulcerative colitis, requiring combined diagnostics and therapy.

Others: Less prevalent autoimmune conditions benefiting from advanced diagnostic techniques.

End Users

Hospitals: Primary diagnostic hubs with integrated laboratories, research affiliations, and long-term patient management capabilities.

Diagnostic Centers: Specialized centers providing high-precision testing and early detection services.

Others: Clinics, specialty labs, and mobile health platforms contributing to market reach.

Regional Analysis

United States

The U.S. dominates the North American autoimmune diagnostics market due to high disease prevalence, advanced healthcare infrastructure, and substantial R&D investment. Approximately 1 in 10 individuals in the U.S. population is affected by autoimmune disorders. Key players like Quest Diagnostics and LabCorp drive market growth through innovative testing solutions, telehealth services, and preventive care programs.

Notable developments include CerraCap Ventures’ investment in Predicta Med (February 2023), a startup focusing on early detection and management of immune-related disorders, underscoring venture capital interest in diagnostic innovation.

Canada

Canada benefits from universal healthcare coverage, ensuring access to essential diagnostic services. The country has a well-established laboratory network, robust research collaborations, and high public awareness, driving demand for autoimmune diagnostics. In April 2025, Health Canada approved SPINEstat™, a blood test for axial spondyloarthritis, highlighting innovation in autoimmune diagnostics.

Mexico

Mexico’s autoimmune diagnostics market is growing steadily due to increased awareness and improved healthcare access. Urban hospitals and diagnostic laboratories are adopting advanced technologies, while government healthcare reforms and international collaborations enhance diagnostic capabilities. Rural access remains a challenge but is improving with ongoing initiatives.

Market Insights by Disease Segment

Systemic Autoimmune Disease Diagnostics

Conditions like lupus and multiple sclerosis require comprehensive testing including blood panels, autoantibody assays, and imaging studies. Early detection programs and government-sponsored research facilitate rapid, precise diagnosis, supporting better disease management.

Localized Autoimmune Disease Diagnostics

Localized conditions such as psoriasis and Hashimoto’s thyroiditis rely on targeted diagnostics through dermatology and endocrinology networks. Growing awareness and specialized clinics drive demand in this segment, supported by companion diagnostics development.

Diabetes Diagnostics

Type 1 diabetes is increasingly prevalent among children and young adults in North America. Autoantibody testing, insulin monitoring, and glucose tracking are critical for early intervention and disease management. Public health campaigns and pediatric screening programs further boost adoption.

Rheumatic Disease Diagnostics

Rheumatic disorders, including rheumatoid arthritis, require diagnostic tools like RF, anti-CCP tests, and imaging scans. Networks of rheumatology clinics, patient advocacy groups, and clinical trials promote early and accurate diagnosis.

Key Players in the North America Autoimmune Disease Diagnostics Market

Bio-Rad Laboratories: Specializes in diagnostic equipment and reagents for autoimmune diseases.

Abbott Laboratories: Offers advanced diagnostics and immunoassays.

Roche Diagnostics: Provides comprehensive testing solutions including molecular diagnostics.

Quest Diagnostics Incorporated: Leading provider of laboratory testing and data-driven diagnostics.

Thermo Fisher Scientific Inc.: Supplies equipment, reagents, and lab services for autoimmune testing.

BioMerieux SA: Develops diagnostic solutions with a focus on precision and reliability.

Myriad Genetics, Inc.: Innovates in molecular diagnostics and biomarker testing.

Siemens Healthineers: Delivers integrated diagnostics platforms and imaging solutions.

These companies focus on R&D, strategic partnerships, and technology integration to maintain a competitive edge in the evolving autoimmune diagnostics market.

Conclusion

The North America Autoimmune Disease Diagnostics Market is poised for robust growth between 2025 and 2033, driven by rising disease prevalence, technological advancements, and supportive healthcare infrastructure. Despite challenges such as high testing costs and diagnostic complexity, the market benefits from government initiatives, reimbursement policies, and growing public awareness.

Future growth is expected to be supported by integration of advanced diagnostics, personalized medicine, remote monitoring technologies, and continuous innovation in therapeutic and monitoring solutions. Companies that adapt to shifting healthcare needs, invest in R&D, and leverage digital platforms will be best positioned to capitalize on the growing demand for autoimmune disease diagnostics in North America.

Note: If you need details, data, or insights not covered in this report, we are glad to assist. Through our customization service, we will collect and deliver the information you require, tailored to your specific needs. Share your requirements with us, and we will update the report to align with your expectations.